Pharma BD Deal Intelligence
Eli Lilly and Company / Organovo Holdings, Inc.
2025 · Asset Purchase · $50M · Complete
Organovo announced that Eli Lilly and Company will acquire Organovo's FXR program, including lead asset FXR314, obtaining all commercial and intellectual property rights for worldwide development. The company release states Organovo will receive an upfront payment plus milestones payable as FXR314 achieves key regulatory and commercial milestones, but does not quantify them. FierceBiotech reported the transaction as a $10M upfront with up to $50M in total value; that figure is trade-press sourced, not company-disclosed.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Feb 25, 2025
- Deal value $50M
- Deal type Asset Purchase
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals · Eli Lilly and Company deals